Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 11,411 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 11,411 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $296,800.11. Following the completion of the sale, the chief executive officer directly owned 27,362 shares of the company’s stock, valued at approximately $711,685.62. This represents a 29.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock opened at $26.21 on Friday. The business’s 50 day moving average price is $28.69 and its 200 day moving average price is $31.17. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics, Inc. has a one year low of $14.27 and a one year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). On average, research analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Wall Street Analysts Forecast Growth

MAZE has been the topic of several recent analyst reports. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. BTIG Research reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, August 12th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics News Summary

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Institutional Trading of Maze Therapeutics

Hedge funds have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. grew its holdings in shares of Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares in the last quarter. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics in the second quarter worth $133,502,907. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics in the second quarter worth $122,983,582. BlackRock Inc. purchased a new stake in shares of Maze Therapeutics during the second quarter worth $104,525,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Maze Therapeutics in the second quarter valued at $101,764,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.